WallStreetZenWallStreetZen

NASDAQ: CTKB
Cytek Biosciences Inc Earnings Dates, Reports, Calls

Buy CTKB*
*Your capital is at risk. Other fees apply.
OverviewForecastEarnings
RevenueDividendOwnership
Cytek Biosciences earnings were -$11.3M for the trailing 12 months ending Mar 31, 2025, with 48.3% growth year over year. The latest CTKB earnings report on Mar 31, 2025 announced Q1 2025 earnings of -$11.4M, down 218.2% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, CTKB reported annual earnings of -$6.0M, with -50.4% growth. The next CTKB earnings date is Aug 12, 2025.

CTKB past earnings growth

How has CTKB's earnings growth performed historically?

Company
48.32%
Industry
50.69%
Market
33.9%
CTKB's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
CTKB's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Market Performance
CTKB's earnings growth is accelerating... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

CTKB earnings history

Current Revenue
$197.1M
Current Earnings
-$11.3M
Current Profit Margin
-5.7%

CTKB Return on Equity

Current Company
-2.9%
Current Industry
7.5%
Current Market
31.3%
CTKB's Return on Equity (-2.9%)... subscribe to Premium to read more.
High Return on Equity Performance

CTKB undefined

Current Company
-2.3%
Current Industry
8.7%
CTKB is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when CTKB announces earnings.

CTKB undefined

Current Company
-0.69%
Current Industry
9.1%
CTKB's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

CTKB vs Medical Device Stocks

TickerEBITDAEarningsY/Y EarningsEPS
CTKB$8.03M-$11.25M+1,755.75%$16,603.78
PACB-$232.04M-$657.75MN/A-$2.28
OFIX-$31.63M-$143.07MN/A-$3.69
SRDX-$1.76M-$19.86MN/A-$1.40
BFLY-$53.30M-$64.70MN/A-$0.29
View Top Medical Device Stocks

CTKB earnings dates

Next earnings date
Aug 12, 2025

Cytek Biosciences Earnings Reports & History FAQ

What were Cytek Biosciences's earnings last quarter?

On CTKB's earnings call on Invalid Date, Cytek Biosciences (NASDAQ: CTKB) reported Q1 2025 earnings per share (EPS) of -$0.09, up 80% year over year. Total CTKB earnings for the quarter were -$11.40 million. In the same quarter last year, Cytek Biosciences's earnings per share (EPS) was -$0.05.

If you're new to stock investing, here's how to buy Cytek Biosciences stock.

When does Cytek Biosciences report earnings?

The next CTKB earnings call is Invalid Date. Add CTKB to your watchlist to be reminded of Cytek Biosciences's next earnings date.

Is Cytek Biosciences profitable or losing money?

As of the last Cytek Biosciences earnings report, Cytek Biosciences is currently losing money. Cytek Biosciences's net profit (also called net income) for the twelve months ending Mar 31, 2025 was -$11.25 million, a 2.24% decrease year over year.

What was CTKB's earnings growth in the past year?

As of Cytek Biosciences's earnings date in Invalid Date, Cytek Biosciences's earnings has grown 48.32% year over year. This is 2.38 percentage points lower than the US Medical Devices industry earnings growth rate of 50.69%. CTKB earnings in the past year totalled -$11.25 million.

What are Cytek Biosciences's earnings expectations?

The current EPS estimate for Cytek Biosciences's earnings report in Invalid Date is -$0.04.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
OSZAR »